Sintilimab + Carboplatin + Etoposide + Ifosfamide + Placebo + Carboplatin + Etoposide + Ifosfamide
Phase 3UNKNOWN 0 views this week 0 watching💤 Quiet
Interest: 36/100
36
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Classic Hodgkin's Lymphoma
Conditions
Classic Hodgkin's Lymphoma
Trial Timeline
Oct 21, 2019 → Dec 31, 2024
NCT ID
NCT04044222About Sintilimab + Carboplatin + Etoposide + Ifosfamide + Placebo + Carboplatin + Etoposide + Ifosfamide
Sintilimab + Carboplatin + Etoposide + Ifosfamide + Placebo + Carboplatin + Etoposide + Ifosfamide is a phase 3 stage product being developed by Innovent Biologics for Classic Hodgkin's Lymphoma. The current trial status is unknown. This product is registered under clinical trial identifier NCT04044222. Target conditions include Classic Hodgkin's Lymphoma.
What happened to similar drugs?
0 of 2 similar drugs in Classic Hodgkin's Lymphoma were approved
Approved (0) Terminated (1) Active (1)
Hype Score Breakdown
Clinical
17
Activity
4
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04044222 | Phase 3 | UNKNOWN |
Competing Products
15 competing products in Classic Hodgkin's Lymphoma
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Camrelizumab + Investigator's choice of Chemotherapy | Jiangsu Hengrui Medicine | Phase 3 | 36 |
| Sabestomig (AZD7789) | AstraZeneca | Phase 1 | 29 |
| THOR-707 + Pembrolizumab | Merck | Phase 2 | 27 |
| Pembrolizumab + Doxorubicin + Vinblastine + Dacarbazine + Brentuximab vedotin | Merck | Phase 2 | 42 |
| Pembrolizumab + Doxorubicin + Vinblastine + Dacarbazine + Bleomycin + Etoposide + Cyclophosphamide + Vincristine + Procarbazine + Prednisone | Merck | Phase 2 | 35 |
| Dacarbazine + Doxorubicin Hydrochloride + Pembrolizumab + Vinblastine Sulfate | Merck | Phase 2 | 31 |
| Carboplatin + Etoposide + Ifosfamide + Pembrolizumab | Merck | Phase 2 | 31 |
| Pembrolizumab (+) Berahyaluronidase alfa | Merck | Phase 2 | 39 |
| Panobinostat | Novartis | Phase 2 | 35 |
| PD1 | Innovent Biologics | Phase 2 | 35 |
| Nivolumab + Autologous CD30.CAR-T + Fludarabine + Bendamustine | Bristol Myers Squibb | Phase 1 | 33 |
| Nivolumab + Ipilimumab | Bristol Myers Squibb | Phase 2 | 31 |
| AK129 + AK117 | Akeso | Phase 1/2 | 39 |
| Tislelizumab + Salvage Chemotherapy | BeOne Medicines | Phase 3 | 29 |
| GEN3017 | Genmab | Phase 1/2 | 21 |